We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Bioscience Vct | LSE:BVP | London | Ordinary Share | GB0031256109 | ORD 50P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 0.00 | - |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| 0 | 0 | N/A | 0 |
Thursday 25 July 2024
Half-year Report
Unaudited Half-year Report for the six months ended 30 June 2024
Seneca Growth Capital VCT Plc (the "Company")
25 July 2024
The Company is pleased to report that it has published its unaudited Half-year Report and financial statements for the six months ended 30 June 2024.
The associated PDF document can be downloaded by clicking the link below at the bottom of the RNS announcement.
The Half-year Report may also be downloaded from the Company’s website at https://senecavct.co.uk/reports-documents/.
In order to ensure that shareholders receive regular information in respect of their investment in the Company, we intend to continue to provide a virtual presentation of the interim and annual results as well as a general portfolio update at least twice annually. The details of this year’s virtual interim results shareholder update presentation will be announced via a Regulatory News Service announcement on the London Stock Exchange and will also be made available on our website in due course. Please visit www.senecavct.co.uk to find out more information.
This announcement contains inside information as stipulated under the UK version of the Market Abuse Regulation No 596/2014 which is part of English Law by virtue of the European (Withdrawal) Act 2018, as amended. Upon the publication of this announcement via a Regulatory Information Service, this information is now considered to be in the public domain.
For further information, please contact:
Richard Manley, Seneca Growth Capital VCT Plc at Richard.Manley@senecapartners.co.uk
Siobhan Pycroft, Seneca Partners Limited at Siobhan.Pycroft@senecapartners.co.uk
Attachment
1 Year Bioscience Vct Chart |
1 Month Bioscience Vct Chart |
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
